Mina Xu, MD
Biography
Mina Xu, MD, is a pathologist who specializes in diagnosing blood diseases and blood cancers—also called hematopathology. Her clinical practice focuses on giving the most accurate diagnosis and prognosis on tumors such as lymphoma, leukemia, and myeloma. At Yale School of Medicine, Dr. Xu is the director of hematopathology and is an associate professor in the departments of pathology and of laboratory medicine. Her academic mission is to study the pathogenesis of human hematopoietic malignancies and translate these findings into diagnostic and therapeutic advances in the field.
“Our role as pathologists includes running specialty tests on patient samples, such as protein analysis or molecular genetic testing, and most importantly, interpreting microscopic images of tissue samples,” Dr. Xu says, adding that she occasionally speaks directly to patients who are interested in learning more about their diseases. “Because we make such critical decisions that guide treatment, we should not be separated from patient care.”
Dr. Xu believes a single biopsy can be thought of as a piece of a larger story. “When you see a tumor evolving from different biopsies, you can put that part of the story into a larger narrative and help patients understand how the disease is changing,” says Dr. Xu. “Some of the success stories in my field center around finding ways to tailor our treatment to the specific genetic abnormality of an otherwise fatal cancer and make it a chronic or curable condition.”
Titles
- Professor of Pathology
- Director of Hematopathology, Pathology
- Director, Expert Consultation Practice, Pathology
Education & Training
- FellowshipBrigham & Women's Hospital (2011)
- ResidencyYale-New Haven Hospital (2010)
- MDUniversity of California at San Francisco (2006)
- BAHarvard University, Biology (2000)
Additional Information
- American Society of Hematology Trainee Grant: American Society of Hematology (2005)
- Weizmann Institute of Science Scholarship: Weizmann (1996)
- Westinghouse Science Award: Westinghouse (1996)
- National Science Foundation Trainee Grant: National Science Foundation (1994)
- AB of Pathology, Anatomic & Clinical Pathology (2010)
- Liu Y, DiStasio M, Su G, Asashima H, Enninful A, Qin X, Deng Y, Nam J, Gao F, Bordignon P, Cassano M, Tomayko M, Xu M, Halene S, Craft J, Hafler D, Fan R. High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq. Nature Biotechnology 2023, 41: 1405-1409. PMID: 36823353, PMCID: PMC10567548, DOI: 10.1038/s41587-023-01676-0.
- Wong J, Roy S, McNiff J, Xu M. IRF8 in Conjunction With CD123 and CD20 to Distinguish Lupus Erythematosus Panniculitis From Subcutaneous Panniculitis-like T-Cell Lymphoma. The American Journal Of Surgical Pathology 2023, 47: 1425-1431. PMID: 37767989, DOI: 10.1097/pas.0000000000002133.
- Baraban E, Hu S, Hui P, Podoltsev N, Cooper D, Xu M. Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients. Bone Marrow Transplantation 2016, 52: 634-637. PMID: 27991892, DOI: 10.1038/bmt.2016.332.
- Verma A, Xu ML. Emerging Immunohistochemical Biomarkers for Myeloid Neoplasms. Archives Of Pathology & Laboratory Medicine 2022, 147: 403-412. PMID: 35533352, DOI: 10.5858/arpa.2021-0558-ra.
- McQuaid DC, Panse G, Wang WL, Pinkus GS, Katz SG, Xu ML. Global assessment of IRF8 as a novel cancer biomarker. Human Pathology 2022, 122: 1-10. PMID: 35085599, PMCID: PMC10621657, DOI: 10.1016/j.humpath.2022.01.004.
- Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 2016, 69: 155-158. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.
- Xu ML, Yang B, Carcangiu ML, Hui P. Epithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping. Modern Pathology 2008, 22: 232-238. PMID: 18820674, DOI: 10.1038/modpathol.2008.165.
- Pelland K, Mathews S, Kamath A, Cohen P, Hudnall SD, Cotta CV, Xu ML. Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma. Applied Immunohistochemistry & Molecular Morphology 2018, 26: e101-e106. PMID: 29189264, DOI: 10.1097/pai.0000000000000615.
- Irshaid L, Bleiberg J, Weinberger E, Garritano J, Shallis RM, Patsenker J, Lindenbaum O, Kluger Y, Katz SG, Xu ML. Histopathologic and Machine Deep Learning Criteria to Predict Lymphoma Transformation in Bone Marrow Biopsies. Archives Of Pathology & Laboratory Medicine 2021, 146: 182-193. PMID: 34086849, DOI: 10.5858/arpa.2020-0510-oa.
- Epperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Evens A, Naik S, Kamdar M, Haverkos B, Karmali R, Farooq U, Vose J, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Advances 2024, 8: 5355-5364. PMID: 39189932, PMCID: PMC11568788, DOI: 10.1182/bloodadvances.2024013791.
- Komrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, Travaglino E, Al Ali N, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain A, Aguirre L, Tinsley-Vance S, Schwabkey Z, Chan O, Xie Z, Brunner A, Kuykendall A, Bennett J, Buckstein R, Bejar R, Carraway H, DeZern A, Griffiths E, Halene S, Hasserjian R, Lancet J, List A, Loghavi S, Odenike O, Padron E, Patnaik M, Roboz G, Stahl M, Sekeres M, Steensma D, Savona M, Taylor J, Xu M, Sweet K, Sallman D, Nimer S, Hourigan C, Wei A, Sauta E, D’Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate U, Sanz G, Efficace F, Gore S, Kim T, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang A, Foucar M, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht A, Ades L, Zeidan A, Della Porta M, Syndromes I. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. The Lancet Haematology 2024, 11: e862-e872. PMID: 39393368, DOI: 10.1016/s2352-3026(24)00251-5.
- Bai Z, Zhang D, Gao Y, Tao B, Zhang D, Bao S, Enninful A, Wang Y, Li H, Su G, Tian X, Zhang N, Xiao Y, Liu Y, Gerstein M, Li M, Xing Y, Lu J, Xu M, Fan R. Spatially exploring RNA biology in archival formalin-fixed paraffin-embedded tissues. Cell 2024, 187: 6760-6779.e24. PMID: 39353436, PMCID: PMC11568911, DOI: 10.1016/j.cell.2024.09.001.
- Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, Borate U, Boultwood J, Brunner A, Buckstein R, Carraway H, Churpek J, Daver N, DeZern A, Efficace F, Fenaux P, Figueroa M, Garcia-Manero G, Gore S, Greenberg P, Griffiths E, Halene S, Hourigan C, Kim T, Kim N, Komrokji R, Kutchroo V, List A, Little R, Majeti R, Nazha A, Nimer S, Odenike O, Padron E, Patnaik M, Platzbecker U, Della Porta M, Roboz G, Sallman D, Santini V, Sanz G, Savona M, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Wei A, Xie Z, Xu M, Hasserjian R, Loghavi S. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Modern Pathology 2024, 37: 100615. PMID: 39322118, DOI: 10.1016/j.modpat.2024.100615.
- Prior D, Schmitt A, Louissaint A, Mata D, Massaro S, Nardi V, Xu M. Large B‐cell lymphoma with mystery rearrangement: Applying Hi‐C to the detection of clinically relevant structural abnormalities. British Journal Of Haematology 2024, 205: 1225-1229. PMID: 38924537, DOI: 10.1111/bjh.19611.
- Mata D, Lee J, Shanmugam V, Marcus C, Schrock A, Williams E, Ritterhouse L, Hickman R, Janovitz T, Patel N, Kroger B, Ross J, Mirza K, Oxnard G, Vergilio J, Elvin J, Benhamida J, Decker B, Xu M. Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results. Histopathology 2024, 84: 1224-1237. PMID: 38422618, DOI: 10.1111/his.15168.
- Kim T, Han X, Hu Q, Vandsemb E, Fielder C, Hong J, Kim K, Mason E, Plowman R, Wang J, Wang Q, Zhang J, Badri T, Sanmamed M, Zheng L, Zhang T, Alawa J, Lee S, Zeidan A, Halene S, Pillai M, Chandhok N, Lu J, Xu M, Gore S, Chen L. PD-1H/VISTA mediates immune evasion in acute myeloid leukemia. Journal Of Clinical Investigation 2024, 134 PMID: 38060328, PMCID: PMC10836799, DOI: 10.1172/jci164325.
- Zhou T, Curry C, Khanlari M, Shi M, Cui W, Peker D, Chen W, Wang E, Gao J, Shen Q, Xie W, Jelloul F, King R, Yuan J, Wang X, Zhao C, Obiorah I, Courville E, Nomura E, Cherian S, Xu M, Burack W, Liu H, Jabbour E, Takahashi K, Wang W, Wang S, Khoury J, Medeiros L, Hu S. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood Cancer Journal 2024, 14: 19. PMID: 38272888, PMCID: PMC10810851, DOI: 10.1038/s41408-024-00983-2.
- Verma A, Liburd S, Tobias Z, Isufi I, Pober J, Xu M. Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype. Blood 2023, 142: 2075. DOI: 10.1182/blood-2023-184963.
- Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski D, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore S, List AF, Kutchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa M, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood Advances 2023, 7: 2709-2714. PMID: 36260702, PMCID: PMC10333740, DOI: 10.1182/bloodadvances.2022008747.
- Tang H, Panse G, Braddock D, Perincheri S, Xu M, McNiff J. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression. Journal Of Cutaneous Pathology 2023, 50: 595-600. PMID: 37082914, DOI: 10.1111/cup.14439.
- Mata D, Lee J, Decker B, Shanmugam V, Marcus C, Tukachinsky H, Schrock A, Patel N, Ross J, Oxnard G, Vergilio J, Mirza K, Xu M, Benhamida J. Liquid Biopsy-Based Next-Generation Sequencing Is an Alternative to Tissue Molecular Profiling of Lymphoid, Plasma-Cell, and Myeloid Neoplasms. Blood 2022, 140: 1205-1207. DOI: 10.1182/blood-2022-159106.
- Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia 2022, 36: 2934-2938. PMID: 36335264, DOI: 10.1038/s41375-022-01754-3.
- Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 2022, 36: 2939-2946. PMID: 36266326, DOI: 10.1038/s41375-022-01724-9.
- Hrones M, Harigopal M, Xu M, Abi‐Raad R. Breast implant‐associated anaplastic large‐cell lymphoma: A series of two case reports diagnosed by cytopathology. Diagnostic Cytopathology 2022, 51: e25-e27. PMID: 36066320, DOI: 10.1002/dc.25052.
- Xu ML, Katz SG. Response to Letter to the Editor: IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias but does not Discriminate Between Monoblasts and Plasmacytoid Dendritic Cells. The American Journal Of Surgical Pathology 2022, 46: 1739-1739. PMID: 36040049, DOI: 10.1097/pas.0000000000001961.
- Deng Y, Bartosovic M, Ma S, Zhang D, Kukanja P, Xiao Y, Su G, Liu Y, Qin X, Rosoklija GB, Dwork AJ, Mann JJ, Xu ML, Halene S, Craft JE, Leong KW, Boldrini M, Castelo-Branco G, Fan R. Spatial profiling of chromatin accessibility in mouse and human tissues. Nature 2022, 609: 375-383. PMID: 35978191, PMCID: PMC9452302, DOI: 10.1038/s41586-022-05094-1.
- Mata D, Xu M, Shanmugam V, Tukachinsky H, Schrock A, Ross J, Williams E, Montesion M, Decker B, Vergilio J, Oxnard G, Benhamida J. Liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) for the evaluation of patients with myeloid neoplasms. Journal Of Clinical Oncology 2022, 40: e19064-e19064. DOI: 10.1200/jco.2022.40.16_suppl.e19064.
- Mata D, Shanmugam V, Decker B, Schrock A, Tukachinsky H, Williams E, Ross J, Montesion M, Oxnard G, Vergilio J, Xu M, Benhamida J. Utility of liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in lymphomas and plasma cell neoplasms. Journal Of Clinical Oncology 2022, 40: e19543-e19543. DOI: 10.1200/jco.2022.40.16_suppl.e19543.
- Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology 2022, 35: 1411-1422. PMID: 35562413, PMCID: PMC9926946, DOI: 10.1038/s41379-022-01091-x.
- Gru AA, Lim MS, Dogan A, Horwitz SM, Delabie J, Fu K, Peker D, Reddy VVB, Xu ML, Vij K, Slack GW, Miranda RN, Jagadeesh D, Lisano JM, Hsi ED, Torlakovic E. Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Archives Of Pathology & Laboratory Medicine 2022, 147: 79-86. PMID: 35472771, DOI: 10.5858/arpa.2021-0270-oa.
- McQuaid DC, Katz SG, Xu ML. IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas. American Journal Of Clinical Pathology 2022, 158: 173-176. PMID: 35460405, PMCID: PMC10664184, DOI: 10.1093/ajcp/aqac044.
- Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.
- Fan R, Liu Y, DiStasio M, Su G, Asashima H, Enninful A, Qin X, Deng Y, Bordignon P, Cassano M, Tomayko M, Xu M, Halene S, Craft J, Hafler D. Spatial-CITE-seq: spatially resolved high-plex protein and whole transcriptome co-mapping. Research Square 2022 PMID: 35378748, PMCID: PMC8978952, DOI: 10.21203/rs.3.rs-1499315/v1.
- Jawad M, Afkhami M, Ding Y, Zhang X, Li P, Young K, Xu ML, Cui W, Zhao Y, Halene S, Al-Kali A, Viswanatha D, Chen D, He R, Zheng G. DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation. Frontiers In Oncology 2022, 12: 849376. PMID: 35296003, PMCID: PMC8918526, DOI: 10.3389/fonc.2022.849376.
- Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literatureMatsumoto NP, Yuan J, Wang J, Shen Q, Chen X, Kim Y, Zuppan CW, Chang CC, Cui W, Chen D, Shi M, Gisriel SD, Chen M, Xu ML, Pan Z. Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature. Modern Pathology 2022, 35: 865-874. PMID: 35105959, DOI: 10.1038/s41379-022-01014-w.
- Zayac A, Landsburg D, Hughes M, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. Blood 2021, 138: 455. DOI: 10.1182/blood-2021-144308.
- Love C, Pillai R, Ondrejka S, Bhagat G, Chadburn A, McKinney M, Koff J, Soliman D, Czader M, Louissaint A, Li S, Ong C, Behdad A, Evens A, Natkunam Y, Norgaard P, Leppa S, Tse E, Chapman J, Amador C, Fedoriw Y, Bogusz A, Evans A, Goswami R, Juskevicius R, Xu M, Naresh K, Xiong B, Snowden A, Thurman A, Smith E, Dave T, Kositsky R, Thakkar D, Russell V, Roth C, Dave S. The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas. Blood 2021, 138: 2213. DOI: 10.1182/blood-2021-151346.
- Johnson JE, McGuone D, Xu ML, Jane-Wit D, Mitchell RN, Libby P, Pober JS. Coronavirus Disease 2019 (COVID-19) Coronary Vascular Thrombosis Correlation with Neutrophil but Not Endothelial Activation. American Journal Of Pathology 2021, 192: 112-120. PMID: 34599881, PMCID: PMC8479934, DOI: 10.1016/j.ajpath.2021.09.004.
- Li P, Biancon G, Patel T, Pan Z, Kothari S, Halene S, Prebet T, Xu ML. Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases. Frontiers In Oncology 2021, 11: 730503. PMID: 34589432, PMCID: PMC8474637, DOI: 10.3389/fonc.2021.730503.
- Li P, Yuan J, Ahmed FS, McHenry A, Fu K, Yu G, Cheng H, Xu ML, Rimm DL, Pan Z. High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis. Frontiers In Oncology 2021, 11: 701492. PMID: 34527580, PMCID: PMC8435777, DOI: 10.3389/fonc.2021.701492.
- Gru AA, Bacchi CE, Pulitzer M, Bhagat G, Kempf W, Robson A, Plaza JA, Pincus L, Raghavan S, Xu M, da Silva T, Salavaggione AL, Subtil A, Battistella M. Secondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients. Journal Of Cutaneous Pathology 2021, 48: 1367-1378. PMID: 34089205, PMCID: PMC9555338, DOI: 10.1111/cup.14077.
- Katz SG, Edappallath S, Xu ML. IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias. The American Journal Of Surgical Pathology 2021, 45: 1391-1398. PMID: 34172624, DOI: 10.1097/pas.0000000000001765.
- Gisriel S, Hung K, Braddock D, Seropian S, Foss F, Robert M, Xu M. Simultaneous colonic T-cell lymphoma and graft-versus-host disease: A rare diagnosis. Human Pathology Reports 2021, 24: 200507. DOI: 10.1016/j.ehpc.2021.200507.
- Gu SX, Pan Z, Xu ML. Thinking outside the cavity: Effusion lymphoma primary to bone marrow. Clinical Case Reports 2021, 9: e04100. PMID: 34026143, PMCID: PMC8136446, DOI: 10.1002/ccr3.4100.
- Song Y, Shan L, Gbyli R, Liu W, Strowig T, Patel A, Fu X, Wang X, Xu ML, Gao Y, Qin A, Bruscia EM, Tebaldi T, Biancon G, Mamillapalli P, Urbonas D, Eynon E, Gonzalez DG, Chen J, Krause DS, Alderman J, Halene S, Flavell RA. Combined liver–cytokine humanization comes to the rescue of circulating human red blood cells. Science 2021, 371: 1019-1025. PMID: 33674488, PMCID: PMC8292008, DOI: 10.1126/science.abe2485.
- Foss F, Ahmed A, Xu M. Gamma–Delta T‐cell Lymphomas. 2021, 203-210. DOI: 10.1002/9781119671336.ch15.
- Verma R, Branagan AR, Xu ML, Flavell RA, Dhodapkar KM, Dhodapkar MV. Role of MBD3-SOX2 axis in residual myeloma following pomalidomide. Leukemia 2021, 35: 3319-3323. PMID: 33603141, PMCID: PMC8371090, DOI: 10.1038/s41375-021-01145-0.
- Weinberg OK, Chisholm KM, Ok CY, Fedoriw Y, Grzywacz B, Kurzer JH, Mason EF, Moser KA, Bhattacharya S, Xu M, Babu D, Foucar K, Tam W, Bagg A, Orazi A, George TI, Wang W, Wang SA, Arber DA, Hasserjian RP. Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology 2021, 34: 1358-1366. PMID: 33526873, DOI: 10.1038/s41379-021-00739-4.
- Morrow JS, Gershkovich P, Gibson J, Gilshannon M, Kowalski D, Levi AW, Nguyen DX, Rimm DL, Xu ML, Sinard J. Measuring Faculty Effort: A Quantitative Approach That Aligns Personal and Institutional Goals in Pathology at Yale. Academic Pathology 2021, 8: 23742895211047985. PMID: 34646939, PMCID: PMC8504692, DOI: 10.1177/23742895211047985.
- Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.
- Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Reviews 2020, 47: 100773. PMID: 33213985, DOI: 10.1016/j.blre.2020.100773.
- Panse G, Subtil A, McNiff JM, Glusac EJ, Ko CJ, Galan A, Myung P, Xu ML. Cutaneous Involvement in Plasma Cell Myeloma. American Journal Of Clinical Pathology 2020, 155: 106-116. PMID: 32885235, DOI: 10.1093/ajcp/aqaa122.
- Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nature Communications 2020, 11: 3549. PMID: 32669548, PMCID: PMC7363864, DOI: 10.1038/s41467-020-17175-8.
- Lin N, Vargas-Pinto S, Gisriel S, Xu M, Gibson CE. Diffuse large B-cell and follicular lymphoma presenting as a slowly growing compressive goiter: A case report and literature review. International Journal Of Surgery Case Reports 2020, 72: 615-619. PMID: 32698301, PMCID: PMC7334388, DOI: 10.1016/j.ijscr.2020.06.029.
- Bar N, Costa F, Das R, Duffy A, Samur M, McCachren S, Gettinger S, Neparidze N, Parker TL, Bailur JK, Pendleton K, Bajpai R, Zhang L, Xu ML, Anderson T, Giuliani N, Nooka A, Cho HJ, Raval A, Shanmugam M, Dhodapkar KM, Dhodapkar M. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight 2020, 5 PMID: 32427579, PMCID: PMC7406262, DOI: 10.1172/jci.insight.129353.
- Kuhny M, Forbes LR, Çakan E, Vega-Loza A, Kostiuk V, Dinesh RK, Glauzy S, Stray-Pedersen A, Pezzi AE, Hanson IC, Vargas-Hernandez A, Xu ML, Akdemir Z, Jhangiani SN, Muzny DM, Gibbs RA, Lupski JR, Chinn IK, Schatz DG, Orange JS, Meffre E. Disease-associated CTNNBL1 mutation impairs somatic hypermutation by decreasing nuclear AID. Journal Of Clinical Investigation 2020, 130: 4411-4422. PMID: 32484799, PMCID: PMC7410074, DOI: 10.1172/jci131297.
- Pan Z, Xu ML. T-cell and NK-cell lymphomas in the lung. Seminars In Diagnostic Pathology 2020, 37: 273-282. PMID: 32448591, DOI: 10.1053/j.semdp.2020.04.003.
- Irshaid L, Xu M. Major Subtypes of Mature T- and NK-Cell Neoplasms. Practical Anatomic Pathology 2020, 175-188. DOI: 10.1007/978-3-030-32189-5_8.
- Toki MI, Kumar D, Ahmed FS, Rimm DL, Xu ML. Benign lymph node microenvironment is associated with response to immunotherapy. Precision Clinical Medicine 2020, 3: 44-53. PMID: 35693430, PMCID: PMC8985791, DOI: 10.1093/pcmedi/pbaa003.
- Nair S, Bar N, Xu ML, Dhodapkar M, Mistry PK. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Molecular Genetics And Metabolism 2020, 129: 286-291. PMID: 32044242, PMCID: PMC8223251, DOI: 10.1016/j.ymgme.2020.01.009.
- Shallis RM, Patel TH, Podoltsev NA, Xu ML, Azar MM, Gore SD. Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia. Leukemia Research 2020, 90: 106315. PMID: 32036123, DOI: 10.1016/j.leukres.2020.106315.
- Maracaja DLV, Puthenpura V, Pels SG, O’Malley D, Sklar JL, Finberg KE, Xu ML. EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas. Applied Immunohistochemistry & Molecular Morphology 2019, 28: 725-730. PMID: 31789821, DOI: 10.1097/pai.0000000000000820.
- Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation. Blood 2019, 134: 4055. DOI: 10.1182/blood-2019-128888.
- Ma J, Nie K, Inghirami G, Eng K, Elemento O, Au-Yeung R, Shen Y, Srivastava G, Gong J, Xu M, Tan L, Tam W. Heterogeneous Genetic Alterations and Novel Pathogenic Pathways in Relapsed DLBCL Revealed By Whole Exome Sequencing. Blood 2019, 134: 2770. DOI: 10.1182/blood-2019-125448.
- Irshaid L, Xu ML. ALCL by any other name: the many facets of anaplastic large cell lymphoma. Pathology 2019, 52: 100-110. PMID: 31706671, DOI: 10.1016/j.pathol.2019.09.007.
- Xu ML, Gabali A, Hsi ED, Fedoriw Y, Vij K, Salama ME, Ramchandren R, O’Malley D, Wick MR, Battistella M, Gru AA. Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. The American Journal Of Surgical Pathology 2019, 44: e1-e14. PMID: 31567279, DOI: 10.1097/pas.0000000000001368.
- Xu M. Hematopathology. Surgical Pathology Clinics 2019, 12: xi. DOI: 10.1016/j.path.2019.05.001.
- Wang JD, Katz SG, Morgan EA, Yang DT, Pan X, Xu ML. Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. Human Pathology 2019, 93: 54-64. PMID: 31425695, PMCID: PMC7038910, DOI: 10.1016/j.humpath.2019.08.008.
- Gong Z, Xu ML, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S. Philadelphia chromosome‐negative acute leukemia in patients with chronic myeloid leukemia. American Journal Of Hematology 2019, 94: e256-e259. PMID: 31273842, DOI: 10.1002/ajh.25571.
- Chen PH, Yang Y, O'Malley DP, Xu ML. Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx. Annals Of Diagnostic Pathology 2019, 41: 129-135. PMID: 31247533, DOI: 10.1016/j.anndiagpath.2019.06.007.
- Pan Z, Xu ML. Histiocytic and Dendritic Cell Neoplasms. Surgical Pathology Clinics 2019, 12: 805-829. PMID: 31352989, DOI: 10.1016/j.path.2019.03.013.
- Goldfinger M, Xu M, Bertino JR, Cooper DL. Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 2019, 19: e307-e311. PMID: 30926391, DOI: 10.1016/j.clml.2019.02.012.
- Yuan J, Li S, Liu X, Su RJ, Chen M, Wu X, Zheng G, Smith LM, Wang L, Li Y, Liu C, Zhou J, Shen Q, Zhang L, Wang E, Xu ML, Pan Z. Mantle Cell Lymphoma With Mantle Zone Growth Pattern. American Journal Of Clinical Pathology 2019, 152: 132-145. PMID: 31140550, DOI: 10.1093/ajcp/aqz043.
- Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, Xu ML, Prebet T, Mason EF, Seegmiller AC, Morgan EA, Steensma DP, Winer ES, Wong WJ, Hasserjian RP, Weinberg OK. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Advances 2019, 3: 1540-1545. PMID: 31085507, PMCID: PMC6517660, DOI: 10.1182/bloodadvances.2019000090.
- Shallis RM, Gleeson S, Azar M, Malinis M, Xu ML, Seropian SE, Gowda L, Zeidan AM. Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations. Leukemia & Lymphoma 2019, 60: 2584-2587. PMID: 30943051, DOI: 10.1080/10428194.2019.1594221.
- Song Y, Rongvaux A, Taylor A, Jiang T, Tebaldi T, Balasubramanian K, Bagale A, Terzi YK, Gbyli R, Wang X, Fu X, Gao Y, Zhao J, Podoltsev N, Xu M, Neparidze N, Wong E, Torres R, Bruscia EM, Kluger Y, Manz MG, Flavell RA, Halene S. A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. Nature Communications 2019, 10: 366. PMID: 30664659, PMCID: PMC6341122, DOI: 10.1038/s41467-018-08166-x.
- Kumar D, Xu ML. Corrigendum: Microenvironment Cell Contribution to Lymphoma Immunity. Frontiers In Oncology 2018, 8: 522. PMID: 30460201, PMCID: PMC6237016, DOI: 10.3389/fonc.2018.00522.
- Shallis RM, Xu ML, Podoltsev NA, Curtis SA, Considine BT, Khanna SR, Siddon AJ, Zeidan AM. Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice. Annals Of Hematology 2018, 97: 2333-2343. PMID: 30109425, DOI: 10.1007/s00277-018-3474-7.
- Conviction in the face of affliction: a case series of Jehovah’s Witnesses with myeloid malignanciesShallis RM, Xu ML, Curtis SA, Medoff E, Mixon R, Folkers A, Zeidan AM. Conviction in the face of affliction: a case series of Jehovah’s Witnesses with myeloid malignancies. Annals Of Hematology 2018, 97: 2245-2248. PMID: 30088044, DOI: 10.1007/s00277-018-3459-6.
- Kumar D, Xu ML. Microenvironment Cell Contribution to Lymphoma Immunity. Frontiers In Oncology 2018, 8: 288. PMID: 30101129, PMCID: PMC6073855, DOI: 10.3389/fonc.2018.00288.
- Romberg N, Le Coz C, Glauzy S, Schickel JN, Trofa M, Nolan BE, Paessler M, Xu M, Lambert MP, Lakhani SA, Khokha MK, Jyonouchi S, Heimall J, Takach P, Maglione PJ, Catanzaro J, Hsu FI, Sullivan KE, Cunningham-Rundles C, Meffre E. Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses. Journal Of Allergy And Clinical Immunology 2018, 143: 258-265. PMID: 29935219, PMCID: PMC6400323, DOI: 10.1016/j.jaci.2018.06.012.
- Rahmani M, Halene S, Xu ML. Small Cell Variant of Intravascular Large B‐Cell Lymphoma: Highlighting a Potentially Fatal and Easily Missed Diagnosis. BioMed Research International 2018, 2018: 9413015. PMID: 29850589, PMCID: PMC5903319, DOI: 10.1155/2018/9413015.
- Kini Bailur J, Mehta S, Zhang L, Neparidze N, Parker T, Bar N, Anderson T, Xu ML, Dhodapkar KM, Dhodapkar MV. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Advances 2017, 1: 2343-2347. PMID: 29296884, PMCID: PMC5729633, DOI: 10.1182/bloodadvances.2017012732.
- Xu ML, O’Malley D. Lymph node stromal and vascular proliferations. Seminars In Diagnostic Pathology 2017, 35: 67-75. PMID: 29173940, DOI: 10.1053/j.semdp.2017.11.004.
- Astle JM, Xu ML, Friedman T, Brown E. Limitations of poor bone marrow aspirations (for an accurate diagnosis) despite the multimodal analytical era: A longitudinal retrospective study. American Journal Of Hematology 2017, 92: e600-e602. PMID: 28670759, DOI: 10.1002/ajh.24839.
- Sharma P, Balasingham S, Stawiarski K, Rahmani M, Costantino A, Sharma P, Xu M, Masoud A. Burkitt lymphoma as a lead point for jejunojejunal intussusception in a human immunodeficiency virus patient. Clinical Journal Of Gastroenterology 2017, 10: 342-350. PMID: 28523628, DOI: 10.1007/s12328-017-0747-y.
- Onuoha C, Arshad J, Astle J, Xu M, Halene S. Novel Developments in Leukopenia and Pancytopenia. Primary Care Clinics In Office Practice 2016, 43: 559-573. PMID: 27866577, DOI: 10.1016/j.pop.2016.07.005.
- Zeidan AM, Xu M, Steensma DP. The importance of erythroblast enumeration in myeloid neoplasia. Annals Of Hematology 2016, 96: 329-330. PMID: 27771743, DOI: 10.1007/s00277-016-2862-0.
- Kim TK, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, Stahl M, Gore SD, Zeidan AM. Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. Annals Of Hematology 2016, 95: 1895-1898. PMID: 27468851, PMCID: PMC10955604, DOI: 10.1007/s00277-016-2761-4.
- Simmons NR, Xu ML, Tavassoli FA, Geisel J, Killelea B, Philpotts LE. A Rare Presentation of Rosai‐Dorfman Disease as a Breast Mass. The Breast Journal 2016, 22: 581-583. PMID: 27345754, DOI: 10.1111/tbj.12635.
- Gauthier AC, Nguyen A, Munday WR, Xu ML, Materin MA. Anterior Chamber Non-Hodgkin Lymphoma of the Iris Masquerading as Uveitis-Glaucoma-Hyphema Syndrome. Ocular Oncology And Pathology 2016, 2: 230-233. PMID: 27843901, PMCID: PMC5091236, DOI: 10.1159/000445119.
- Stahl M, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Annals Of Hematology 2016, 95: 1197-1200. PMID: 27068405, PMCID: PMC7479634, DOI: 10.1007/s00277-016-2664-4.
- Xu M, Li L, Pittenger C. Ablation of fast-spiking interneurons in the dorsal striatum, recapitulating abnormalities seen post-mortem in Tourette syndrome, produces anxiety and elevated grooming. Neuroscience 2016, 324: 321-329. PMID: 26968763, PMCID: PMC4838496, DOI: 10.1016/j.neuroscience.2016.02.074.
- Xu ML, Fedoriw Y. Lymphoma Microenvironment and Immunotherapy. Surgical Pathology Clinics 2016, 9: 93-100. PMID: 26940270, DOI: 10.1016/j.path.2015.10.001.
- Verma R, Mai Z, Xu M, Zhang L, Dhodapkar K, Dhodapkar M. Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs. Blood 2015, 126: 913. DOI: 10.1182/blood.v126.23.913.913.
- Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary. Oncotarget 2015, 6: 13933-13945. PMID: 26101854, PMCID: PMC4546442, DOI: 10.18632/oncotarget.4324.
- Ho C, Yao X, Tian L, Li FY, Podoltsev N, Xu ML. The authors' reply. American Journal Of Clinical Pathology 2015, 143: 309. PMID: 25738202.
- Munday WR, Kapur LH, Xu M, Zhang X. Russell body duodenitis with immunoglobulin kappa light chain restriction. World Journal Of Gastrointestinal Endoscopy 2015, 7: 73-76. PMID: 25610537, PMCID: PMC4295184, DOI: 10.4253/wjge.v7.i1.73.
- Gibson JF, Kapur L, Sokhn J, Xu M, Foss FM. A fatal case of primary cutaneous gamma–delta T‐cell lymphoma complicated by HLH and cardiac amyloidosis. Clinical Case Reports 2014, 3: 34-38. PMID: 25678971, PMCID: PMC4317209, DOI: 10.1002/ccr3.142.
- Xu ML, Cooper D. Caught in transformation. Blood 2014, 124: 2749. PMID: 25513660, DOI: 10.1182/blood-2014-08-593913.
- Ahmad AK, Hui P, Litkouhi B, Azodi M, Rutherford T, McCarthy S, Xu ML, Schwartz PE, Ratner E. Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital Tract. International Journal Of Gynecological Cancer 2014, 24: 1250-1255. PMID: 25010039, PMCID: PMC8139417, DOI: 10.1097/igc.0000000000000201.
- Ho C, Yao X, Tian L, Li FY, Podoltsev N, Xu ML. Marrow Assessment for Hemophagocytic Lymphohistiocytosis Demonstrates Poor Correlation With Disease Probability. American Journal Of Clinical Pathology 2014, 141: 62-71. PMID: 24343738, DOI: 10.1309/ajcpmd5tjefoovbw.
- Fraser J, Subtil A, Alpdogan O, Seropian S, Cooper D, Xu M, Foss F. Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience. Blood 2013, 122: 5092. DOI: 10.1182/blood.v122.21.5092.5092.
- Varughese N, Duong A, Emre S, Xu M, Lee AI. Venting the Spleen. New England Journal Of Medicine 2013, 369: 1357-1363. PMID: 24088096, DOI: 10.1056/nejmcps1210943.
- Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. Clinical Cancer Research 2013, 19: 3462-3473. PMID: 23674495, PMCID: PMC4102335, DOI: 10.1158/1078-0432.ccr-13-0855.
- Alomari A, Hui P, Xu M. Composite Peripheral T-cell Lymphoma Not Otherwise Specified, and B-cell Small Lymphocytic Lymphoma Presenting With Hemophagocytic Lymphohistiocytosis. International Journal Of Surgical Pathology 2012, 21: 303-308. PMID: 23129836, DOI: 10.1177/1066896912464047.
- Xu M, Schwartz P, Rutherford T, Azodi M, Santin A, Silasi D, Martel M, Hui P. HER‐2/neu receptor gene status in endometrial carcinomas: a tissue microarray study. Histopathology 2009, 56: 269-273. PMID: 20102407, DOI: 10.1111/j.1365-2559.2009.03464.x.
- McClaskey J, Xu M, Snyder EL, Tormey CA. Clinical trials for pathogen reduction in transfusion medicine: A review. Transfusion And Apheresis Science 2009, 41: 217-225. PMID: 19793679, DOI: 10.1016/j.transci.2009.09.008.
- Chiang MY, Xu ML, Histen G, Shestova O, Roy M, Nam Y, Blacklow SC, Sacks DB, Pear WS, Aster JC. Identification of a conserved negative regulatory sequence that influences the leukemogenic activity of NOTCH1. Molecular And Cellular Biology 2006, 26: 6261-71. PMID: 16880534, PMCID: PMC1592797, DOI: 10.1128/MCB.02478-05.
- Malecki MJ, Sanchez-Irizarry C, Mitchell JL, Histen G, Xu ML, Aster JC, Blacklow SC. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Molecular And Cellular Biology 2006, 26: 4642-51. PMID: 16738328, PMCID: PMC1489116, DOI: 10.1128/MCB.01655-05.
- Mega MS, Thompson PM, Cummings JL, Back CL, Xu ML, Zohoori S, Goldkorn A, Moussai J, Fairbanks L, Small GW, Toga AW. Sulcal variability in the Alzheimer's brain: correlations with cognition. Neurology 1998, 50: 145-51. PMID: 9443471.
Biography
Mina Xu, MD, is a pathologist who specializes in diagnosing blood diseases and blood cancers—also called hematopathology. Her clinical practice focuses on giving the most accurate diagnosis and prognosis on tumors such as lymphoma, leukemia, and myeloma. At Yale School of Medicine, Dr. Xu is the director of hematopathology and is an associate professor in the departments of pathology and of laboratory medicine. Her academic mission is to study the pathogenesis of human hematopoietic malignancies and translate these findings into diagnostic and therapeutic advances in the field.
“Our role as pathologists includes running specialty tests on patient samples, such as protein analysis or molecular genetic testing, and most importantly, interpreting microscopic images of tissue samples,” Dr. Xu says, adding that she occasionally speaks directly to patients who are interested in learning more about their diseases. “Because we make such critical decisions that guide treatment, we should not be separated from patient care.”
Dr. Xu believes a single biopsy can be thought of as a piece of a larger story. “When you see a tumor evolving from different biopsies, you can put that part of the story into a larger narrative and help patients understand how the disease is changing,” says Dr. Xu. “Some of the success stories in my field center around finding ways to tailor our treatment to the specific genetic abnormality of an otherwise fatal cancer and make it a chronic or curable condition.”
Titles
- Professor of Pathology
- Director of Hematopathology, Pathology
- Director, Expert Consultation Practice, Pathology
Education & Training
- FellowshipBrigham & Women's Hospital (2011)
- ResidencyYale-New Haven Hospital (2010)
- MDUniversity of California at San Francisco (2006)
- BAHarvard University, Biology (2000)
Additional Information
- American Society of Hematology Trainee Grant: American Society of Hematology (2005)
- Weizmann Institute of Science Scholarship: Weizmann (1996)
- Westinghouse Science Award: Westinghouse (1996)
- National Science Foundation Trainee Grant: National Science Foundation (1994)
- AB of Pathology, Anatomic & Clinical Pathology (2010)
- Liu Y, DiStasio M, Su G, Asashima H, Enninful A, Qin X, Deng Y, Nam J, Gao F, Bordignon P, Cassano M, Tomayko M, Xu M, Halene S, Craft J, Hafler D, Fan R. High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq. Nature Biotechnology 2023, 41: 1405-1409. PMID: 36823353, PMCID: PMC10567548, DOI: 10.1038/s41587-023-01676-0.
- Wong J, Roy S, McNiff J, Xu M. IRF8 in Conjunction With CD123 and CD20 to Distinguish Lupus Erythematosus Panniculitis From Subcutaneous Panniculitis-like T-Cell Lymphoma. The American Journal Of Surgical Pathology 2023, 47: 1425-1431. PMID: 37767989, DOI: 10.1097/pas.0000000000002133.
- Baraban E, Hu S, Hui P, Podoltsev N, Cooper D, Xu M. Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients. Bone Marrow Transplantation 2016, 52: 634-637. PMID: 27991892, DOI: 10.1038/bmt.2016.332.
- Verma A, Xu ML. Emerging Immunohistochemical Biomarkers for Myeloid Neoplasms. Archives Of Pathology & Laboratory Medicine 2022, 147: 403-412. PMID: 35533352, DOI: 10.5858/arpa.2021-0558-ra.
- McQuaid DC, Panse G, Wang WL, Pinkus GS, Katz SG, Xu ML. Global assessment of IRF8 as a novel cancer biomarker. Human Pathology 2022, 122: 1-10. PMID: 35085599, PMCID: PMC10621657, DOI: 10.1016/j.humpath.2022.01.004.
- Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 2016, 69: 155-158. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.
- Xu ML, Yang B, Carcangiu ML, Hui P. Epithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping. Modern Pathology 2008, 22: 232-238. PMID: 18820674, DOI: 10.1038/modpathol.2008.165.
- Pelland K, Mathews S, Kamath A, Cohen P, Hudnall SD, Cotta CV, Xu ML. Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma. Applied Immunohistochemistry & Molecular Morphology 2018, 26: e101-e106. PMID: 29189264, DOI: 10.1097/pai.0000000000000615.
- Irshaid L, Bleiberg J, Weinberger E, Garritano J, Shallis RM, Patsenker J, Lindenbaum O, Kluger Y, Katz SG, Xu ML. Histopathologic and Machine Deep Learning Criteria to Predict Lymphoma Transformation in Bone Marrow Biopsies. Archives Of Pathology & Laboratory Medicine 2021, 146: 182-193. PMID: 34086849, DOI: 10.5858/arpa.2020-0510-oa.
- Epperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Evens A, Naik S, Kamdar M, Haverkos B, Karmali R, Farooq U, Vose J, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Advances 2024, 8: 5355-5364. PMID: 39189932, PMCID: PMC11568788, DOI: 10.1182/bloodadvances.2024013791.
- Komrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, Travaglino E, Al Ali N, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain A, Aguirre L, Tinsley-Vance S, Schwabkey Z, Chan O, Xie Z, Brunner A, Kuykendall A, Bennett J, Buckstein R, Bejar R, Carraway H, DeZern A, Griffiths E, Halene S, Hasserjian R, Lancet J, List A, Loghavi S, Odenike O, Padron E, Patnaik M, Roboz G, Stahl M, Sekeres M, Steensma D, Savona M, Taylor J, Xu M, Sweet K, Sallman D, Nimer S, Hourigan C, Wei A, Sauta E, D’Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate U, Sanz G, Efficace F, Gore S, Kim T, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang A, Foucar M, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht A, Ades L, Zeidan A, Della Porta M, Syndromes I. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. The Lancet Haematology 2024, 11: e862-e872. PMID: 39393368, DOI: 10.1016/s2352-3026(24)00251-5.
- Bai Z, Zhang D, Gao Y, Tao B, Zhang D, Bao S, Enninful A, Wang Y, Li H, Su G, Tian X, Zhang N, Xiao Y, Liu Y, Gerstein M, Li M, Xing Y, Lu J, Xu M, Fan R. Spatially exploring RNA biology in archival formalin-fixed paraffin-embedded tissues. Cell 2024, 187: 6760-6779.e24. PMID: 39353436, PMCID: PMC11568911, DOI: 10.1016/j.cell.2024.09.001.
- Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, Borate U, Boultwood J, Brunner A, Buckstein R, Carraway H, Churpek J, Daver N, DeZern A, Efficace F, Fenaux P, Figueroa M, Garcia-Manero G, Gore S, Greenberg P, Griffiths E, Halene S, Hourigan C, Kim T, Kim N, Komrokji R, Kutchroo V, List A, Little R, Majeti R, Nazha A, Nimer S, Odenike O, Padron E, Patnaik M, Platzbecker U, Della Porta M, Roboz G, Sallman D, Santini V, Sanz G, Savona M, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Wei A, Xie Z, Xu M, Hasserjian R, Loghavi S. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Modern Pathology 2024, 37: 100615. PMID: 39322118, DOI: 10.1016/j.modpat.2024.100615.
- Prior D, Schmitt A, Louissaint A, Mata D, Massaro S, Nardi V, Xu M. Large B‐cell lymphoma with mystery rearrangement: Applying Hi‐C to the detection of clinically relevant structural abnormalities. British Journal Of Haematology 2024, 205: 1225-1229. PMID: 38924537, DOI: 10.1111/bjh.19611.
- Mata D, Lee J, Shanmugam V, Marcus C, Schrock A, Williams E, Ritterhouse L, Hickman R, Janovitz T, Patel N, Kroger B, Ross J, Mirza K, Oxnard G, Vergilio J, Elvin J, Benhamida J, Decker B, Xu M. Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results. Histopathology 2024, 84: 1224-1237. PMID: 38422618, DOI: 10.1111/his.15168.
- Kim T, Han X, Hu Q, Vandsemb E, Fielder C, Hong J, Kim K, Mason E, Plowman R, Wang J, Wang Q, Zhang J, Badri T, Sanmamed M, Zheng L, Zhang T, Alawa J, Lee S, Zeidan A, Halene S, Pillai M, Chandhok N, Lu J, Xu M, Gore S, Chen L. PD-1H/VISTA mediates immune evasion in acute myeloid leukemia. Journal Of Clinical Investigation 2024, 134 PMID: 38060328, PMCID: PMC10836799, DOI: 10.1172/jci164325.
- Zhou T, Curry C, Khanlari M, Shi M, Cui W, Peker D, Chen W, Wang E, Gao J, Shen Q, Xie W, Jelloul F, King R, Yuan J, Wang X, Zhao C, Obiorah I, Courville E, Nomura E, Cherian S, Xu M, Burack W, Liu H, Jabbour E, Takahashi K, Wang W, Wang S, Khoury J, Medeiros L, Hu S. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood Cancer Journal 2024, 14: 19. PMID: 38272888, PMCID: PMC10810851, DOI: 10.1038/s41408-024-00983-2.
- Verma A, Liburd S, Tobias Z, Isufi I, Pober J, Xu M. Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype. Blood 2023, 142: 2075. DOI: 10.1182/blood-2023-184963.
- Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski D, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore S, List AF, Kutchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa M, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood Advances 2023, 7: 2709-2714. PMID: 36260702, PMCID: PMC10333740, DOI: 10.1182/bloodadvances.2022008747.
- Tang H, Panse G, Braddock D, Perincheri S, Xu M, McNiff J. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression. Journal Of Cutaneous Pathology 2023, 50: 595-600. PMID: 37082914, DOI: 10.1111/cup.14439.
- Mata D, Lee J, Decker B, Shanmugam V, Marcus C, Tukachinsky H, Schrock A, Patel N, Ross J, Oxnard G, Vergilio J, Mirza K, Xu M, Benhamida J. Liquid Biopsy-Based Next-Generation Sequencing Is an Alternative to Tissue Molecular Profiling of Lymphoid, Plasma-Cell, and Myeloid Neoplasms. Blood 2022, 140: 1205-1207. DOI: 10.1182/blood-2022-159106.
- Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia 2022, 36: 2934-2938. PMID: 36335264, DOI: 10.1038/s41375-022-01754-3.
- Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 2022, 36: 2939-2946. PMID: 36266326, DOI: 10.1038/s41375-022-01724-9.
- Hrones M, Harigopal M, Xu M, Abi‐Raad R. Breast implant‐associated anaplastic large‐cell lymphoma: A series of two case reports diagnosed by cytopathology. Diagnostic Cytopathology 2022, 51: e25-e27. PMID: 36066320, DOI: 10.1002/dc.25052.
- Xu ML, Katz SG. Response to Letter to the Editor: IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias but does not Discriminate Between Monoblasts and Plasmacytoid Dendritic Cells. The American Journal Of Surgical Pathology 2022, 46: 1739-1739. PMID: 36040049, DOI: 10.1097/pas.0000000000001961.
- Deng Y, Bartosovic M, Ma S, Zhang D, Kukanja P, Xiao Y, Su G, Liu Y, Qin X, Rosoklija GB, Dwork AJ, Mann JJ, Xu ML, Halene S, Craft JE, Leong KW, Boldrini M, Castelo-Branco G, Fan R. Spatial profiling of chromatin accessibility in mouse and human tissues. Nature 2022, 609: 375-383. PMID: 35978191, PMCID: PMC9452302, DOI: 10.1038/s41586-022-05094-1.
- Mata D, Xu M, Shanmugam V, Tukachinsky H, Schrock A, Ross J, Williams E, Montesion M, Decker B, Vergilio J, Oxnard G, Benhamida J. Liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) for the evaluation of patients with myeloid neoplasms. Journal Of Clinical Oncology 2022, 40: e19064-e19064. DOI: 10.1200/jco.2022.40.16_suppl.e19064.
- Mata D, Shanmugam V, Decker B, Schrock A, Tukachinsky H, Williams E, Ross J, Montesion M, Oxnard G, Vergilio J, Xu M, Benhamida J. Utility of liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in lymphomas and plasma cell neoplasms. Journal Of Clinical Oncology 2022, 40: e19543-e19543. DOI: 10.1200/jco.2022.40.16_suppl.e19543.
- Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology 2022, 35: 1411-1422. PMID: 35562413, PMCID: PMC9926946, DOI: 10.1038/s41379-022-01091-x.
- Gru AA, Lim MS, Dogan A, Horwitz SM, Delabie J, Fu K, Peker D, Reddy VVB, Xu ML, Vij K, Slack GW, Miranda RN, Jagadeesh D, Lisano JM, Hsi ED, Torlakovic E. Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Archives Of Pathology & Laboratory Medicine 2022, 147: 79-86. PMID: 35472771, DOI: 10.5858/arpa.2021-0270-oa.
- McQuaid DC, Katz SG, Xu ML. IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas. American Journal Of Clinical Pathology 2022, 158: 173-176. PMID: 35460405, PMCID: PMC10664184, DOI: 10.1093/ajcp/aqac044.
- Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.
- Fan R, Liu Y, DiStasio M, Su G, Asashima H, Enninful A, Qin X, Deng Y, Bordignon P, Cassano M, Tomayko M, Xu M, Halene S, Craft J, Hafler D. Spatial-CITE-seq: spatially resolved high-plex protein and whole transcriptome co-mapping. Research Square 2022 PMID: 35378748, PMCID: PMC8978952, DOI: 10.21203/rs.3.rs-1499315/v1.
- Jawad M, Afkhami M, Ding Y, Zhang X, Li P, Young K, Xu ML, Cui W, Zhao Y, Halene S, Al-Kali A, Viswanatha D, Chen D, He R, Zheng G. DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation. Frontiers In Oncology 2022, 12: 849376. PMID: 35296003, PMCID: PMC8918526, DOI: 10.3389/fonc.2022.849376.
- Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literatureMatsumoto NP, Yuan J, Wang J, Shen Q, Chen X, Kim Y, Zuppan CW, Chang CC, Cui W, Chen D, Shi M, Gisriel SD, Chen M, Xu ML, Pan Z. Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature. Modern Pathology 2022, 35: 865-874. PMID: 35105959, DOI: 10.1038/s41379-022-01014-w.
- Zayac A, Landsburg D, Hughes M, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. Blood 2021, 138: 455. DOI: 10.1182/blood-2021-144308.
- Love C, Pillai R, Ondrejka S, Bhagat G, Chadburn A, McKinney M, Koff J, Soliman D, Czader M, Louissaint A, Li S, Ong C, Behdad A, Evens A, Natkunam Y, Norgaard P, Leppa S, Tse E, Chapman J, Amador C, Fedoriw Y, Bogusz A, Evans A, Goswami R, Juskevicius R, Xu M, Naresh K, Xiong B, Snowden A, Thurman A, Smith E, Dave T, Kositsky R, Thakkar D, Russell V, Roth C, Dave S. The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas. Blood 2021, 138: 2213. DOI: 10.1182/blood-2021-151346.
- Johnson JE, McGuone D, Xu ML, Jane-Wit D, Mitchell RN, Libby P, Pober JS. Coronavirus Disease 2019 (COVID-19) Coronary Vascular Thrombosis Correlation with Neutrophil but Not Endothelial Activation. American Journal Of Pathology 2021, 192: 112-120. PMID: 34599881, PMCID: PMC8479934, DOI: 10.1016/j.ajpath.2021.09.004.
- Li P, Biancon G, Patel T, Pan Z, Kothari S, Halene S, Prebet T, Xu ML. Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases. Frontiers In Oncology 2021, 11: 730503. PMID: 34589432, PMCID: PMC8474637, DOI: 10.3389/fonc.2021.730503.
- Li P, Yuan J, Ahmed FS, McHenry A, Fu K, Yu G, Cheng H, Xu ML, Rimm DL, Pan Z. High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis. Frontiers In Oncology 2021, 11: 701492. PMID: 34527580, PMCID: PMC8435777, DOI: 10.3389/fonc.2021.701492.
- Gru AA, Bacchi CE, Pulitzer M, Bhagat G, Kempf W, Robson A, Plaza JA, Pincus L, Raghavan S, Xu M, da Silva T, Salavaggione AL, Subtil A, Battistella M. Secondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients. Journal Of Cutaneous Pathology 2021, 48: 1367-1378. PMID: 34089205, PMCID: PMC9555338, DOI: 10.1111/cup.14077.
- Katz SG, Edappallath S, Xu ML. IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias. The American Journal Of Surgical Pathology 2021, 45: 1391-1398. PMID: 34172624, DOI: 10.1097/pas.0000000000001765.
- Gisriel S, Hung K, Braddock D, Seropian S, Foss F, Robert M, Xu M. Simultaneous colonic T-cell lymphoma and graft-versus-host disease: A rare diagnosis. Human Pathology Reports 2021, 24: 200507. DOI: 10.1016/j.ehpc.2021.200507.
- Gu SX, Pan Z, Xu ML. Thinking outside the cavity: Effusion lymphoma primary to bone marrow. Clinical Case Reports 2021, 9: e04100. PMID: 34026143, PMCID: PMC8136446, DOI: 10.1002/ccr3.4100.
- Song Y, Shan L, Gbyli R, Liu W, Strowig T, Patel A, Fu X, Wang X, Xu ML, Gao Y, Qin A, Bruscia EM, Tebaldi T, Biancon G, Mamillapalli P, Urbonas D, Eynon E, Gonzalez DG, Chen J, Krause DS, Alderman J, Halene S, Flavell RA. Combined liver–cytokine humanization comes to the rescue of circulating human red blood cells. Science 2021, 371: 1019-1025. PMID: 33674488, PMCID: PMC8292008, DOI: 10.1126/science.abe2485.
- Foss F, Ahmed A, Xu M. Gamma–Delta T‐cell Lymphomas. 2021, 203-210. DOI: 10.1002/9781119671336.ch15.
- Verma R, Branagan AR, Xu ML, Flavell RA, Dhodapkar KM, Dhodapkar MV. Role of MBD3-SOX2 axis in residual myeloma following pomalidomide. Leukemia 2021, 35: 3319-3323. PMID: 33603141, PMCID: PMC8371090, DOI: 10.1038/s41375-021-01145-0.
- Weinberg OK, Chisholm KM, Ok CY, Fedoriw Y, Grzywacz B, Kurzer JH, Mason EF, Moser KA, Bhattacharya S, Xu M, Babu D, Foucar K, Tam W, Bagg A, Orazi A, George TI, Wang W, Wang SA, Arber DA, Hasserjian RP. Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology 2021, 34: 1358-1366. PMID: 33526873, DOI: 10.1038/s41379-021-00739-4.
- Morrow JS, Gershkovich P, Gibson J, Gilshannon M, Kowalski D, Levi AW, Nguyen DX, Rimm DL, Xu ML, Sinard J. Measuring Faculty Effort: A Quantitative Approach That Aligns Personal and Institutional Goals in Pathology at Yale. Academic Pathology 2021, 8: 23742895211047985. PMID: 34646939, PMCID: PMC8504692, DOI: 10.1177/23742895211047985.
- Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.
- Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Reviews 2020, 47: 100773. PMID: 33213985, DOI: 10.1016/j.blre.2020.100773.
- Panse G, Subtil A, McNiff JM, Glusac EJ, Ko CJ, Galan A, Myung P, Xu ML. Cutaneous Involvement in Plasma Cell Myeloma. American Journal Of Clinical Pathology 2020, 155: 106-116. PMID: 32885235, DOI: 10.1093/ajcp/aqaa122.
- Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nature Communications 2020, 11: 3549. PMID: 32669548, PMCID: PMC7363864, DOI: 10.1038/s41467-020-17175-8.
- Lin N, Vargas-Pinto S, Gisriel S, Xu M, Gibson CE. Diffuse large B-cell and follicular lymphoma presenting as a slowly growing compressive goiter: A case report and literature review. International Journal Of Surgery Case Reports 2020, 72: 615-619. PMID: 32698301, PMCID: PMC7334388, DOI: 10.1016/j.ijscr.2020.06.029.
- Bar N, Costa F, Das R, Duffy A, Samur M, McCachren S, Gettinger S, Neparidze N, Parker TL, Bailur JK, Pendleton K, Bajpai R, Zhang L, Xu ML, Anderson T, Giuliani N, Nooka A, Cho HJ, Raval A, Shanmugam M, Dhodapkar KM, Dhodapkar M. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight 2020, 5 PMID: 32427579, PMCID: PMC7406262, DOI: 10.1172/jci.insight.129353.
- Kuhny M, Forbes LR, Çakan E, Vega-Loza A, Kostiuk V, Dinesh RK, Glauzy S, Stray-Pedersen A, Pezzi AE, Hanson IC, Vargas-Hernandez A, Xu ML, Akdemir Z, Jhangiani SN, Muzny DM, Gibbs RA, Lupski JR, Chinn IK, Schatz DG, Orange JS, Meffre E. Disease-associated CTNNBL1 mutation impairs somatic hypermutation by decreasing nuclear AID. Journal Of Clinical Investigation 2020, 130: 4411-4422. PMID: 32484799, PMCID: PMC7410074, DOI: 10.1172/jci131297.
- Pan Z, Xu ML. T-cell and NK-cell lymphomas in the lung. Seminars In Diagnostic Pathology 2020, 37: 273-282. PMID: 32448591, DOI: 10.1053/j.semdp.2020.04.003.
- Irshaid L, Xu M. Major Subtypes of Mature T- and NK-Cell Neoplasms. Practical Anatomic Pathology 2020, 175-188. DOI: 10.1007/978-3-030-32189-5_8.
- Toki MI, Kumar D, Ahmed FS, Rimm DL, Xu ML. Benign lymph node microenvironment is associated with response to immunotherapy. Precision Clinical Medicine 2020, 3: 44-53. PMID: 35693430, PMCID: PMC8985791, DOI: 10.1093/pcmedi/pbaa003.
- Nair S, Bar N, Xu ML, Dhodapkar M, Mistry PK. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Molecular Genetics And Metabolism 2020, 129: 286-291. PMID: 32044242, PMCID: PMC8223251, DOI: 10.1016/j.ymgme.2020.01.009.
- Shallis RM, Patel TH, Podoltsev NA, Xu ML, Azar MM, Gore SD. Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia. Leukemia Research 2020, 90: 106315. PMID: 32036123, DOI: 10.1016/j.leukres.2020.106315.
- Maracaja DLV, Puthenpura V, Pels SG, O’Malley D, Sklar JL, Finberg KE, Xu ML. EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas. Applied Immunohistochemistry & Molecular Morphology 2019, 28: 725-730. PMID: 31789821, DOI: 10.1097/pai.0000000000000820.
- Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation. Blood 2019, 134: 4055. DOI: 10.1182/blood-2019-128888.
- Ma J, Nie K, Inghirami G, Eng K, Elemento O, Au-Yeung R, Shen Y, Srivastava G, Gong J, Xu M, Tan L, Tam W. Heterogeneous Genetic Alterations and Novel Pathogenic Pathways in Relapsed DLBCL Revealed By Whole Exome Sequencing. Blood 2019, 134: 2770. DOI: 10.1182/blood-2019-125448.
- Irshaid L, Xu ML. ALCL by any other name: the many facets of anaplastic large cell lymphoma. Pathology 2019, 52: 100-110. PMID: 31706671, DOI: 10.1016/j.pathol.2019.09.007.
- Xu ML, Gabali A, Hsi ED, Fedoriw Y, Vij K, Salama ME, Ramchandren R, O’Malley D, Wick MR, Battistella M, Gru AA. Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. The American Journal Of Surgical Pathology 2019, 44: e1-e14. PMID: 31567279, DOI: 10.1097/pas.0000000000001368.
- Xu M. Hematopathology. Surgical Pathology Clinics 2019, 12: xi. DOI: 10.1016/j.path.2019.05.001.
- Wang JD, Katz SG, Morgan EA, Yang DT, Pan X, Xu ML. Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. Human Pathology 2019, 93: 54-64. PMID: 31425695, PMCID: PMC7038910, DOI: 10.1016/j.humpath.2019.08.008.
- Gong Z, Xu ML, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S. Philadelphia chromosome‐negative acute leukemia in patients with chronic myeloid leukemia. American Journal Of Hematology 2019, 94: e256-e259. PMID: 31273842, DOI: 10.1002/ajh.25571.
- Chen PH, Yang Y, O'Malley DP, Xu ML. Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx. Annals Of Diagnostic Pathology 2019, 41: 129-135. PMID: 31247533, DOI: 10.1016/j.anndiagpath.2019.06.007.
- Pan Z, Xu ML. Histiocytic and Dendritic Cell Neoplasms. Surgical Pathology Clinics 2019, 12: 805-829. PMID: 31352989, DOI: 10.1016/j.path.2019.03.013.
- Goldfinger M, Xu M, Bertino JR, Cooper DL. Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 2019, 19: e307-e311. PMID: 30926391, DOI: 10.1016/j.clml.2019.02.012.
- Yuan J, Li S, Liu X, Su RJ, Chen M, Wu X, Zheng G, Smith LM, Wang L, Li Y, Liu C, Zhou J, Shen Q, Zhang L, Wang E, Xu ML, Pan Z. Mantle Cell Lymphoma With Mantle Zone Growth Pattern. American Journal Of Clinical Pathology 2019, 152: 132-145. PMID: 31140550, DOI: 10.1093/ajcp/aqz043.
- Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, Xu ML, Prebet T, Mason EF, Seegmiller AC, Morgan EA, Steensma DP, Winer ES, Wong WJ, Hasserjian RP, Weinberg OK. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Advances 2019, 3: 1540-1545. PMID: 31085507, PMCID: PMC6517660, DOI: 10.1182/bloodadvances.2019000090.
- Shallis RM, Gleeson S, Azar M, Malinis M, Xu ML, Seropian SE, Gowda L, Zeidan AM. Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations. Leukemia & Lymphoma 2019, 60: 2584-2587. PMID: 30943051, DOI: 10.1080/10428194.2019.1594221.
- Song Y, Rongvaux A, Taylor A, Jiang T, Tebaldi T, Balasubramanian K, Bagale A, Terzi YK, Gbyli R, Wang X, Fu X, Gao Y, Zhao J, Podoltsev N, Xu M, Neparidze N, Wong E, Torres R, Bruscia EM, Kluger Y, Manz MG, Flavell RA, Halene S. A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. Nature Communications 2019, 10: 366. PMID: 30664659, PMCID: PMC6341122, DOI: 10.1038/s41467-018-08166-x.
- Kumar D, Xu ML. Corrigendum: Microenvironment Cell Contribution to Lymphoma Immunity. Frontiers In Oncology 2018, 8: 522. PMID: 30460201, PMCID: PMC6237016, DOI: 10.3389/fonc.2018.00522.
- Shallis RM, Xu ML, Podoltsev NA, Curtis SA, Considine BT, Khanna SR, Siddon AJ, Zeidan AM. Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice. Annals Of Hematology 2018, 97: 2333-2343. PMID: 30109425, DOI: 10.1007/s00277-018-3474-7.
- Conviction in the face of affliction: a case series of Jehovah’s Witnesses with myeloid malignanciesShallis RM, Xu ML, Curtis SA, Medoff E, Mixon R, Folkers A, Zeidan AM. Conviction in the face of affliction: a case series of Jehovah’s Witnesses with myeloid malignancies. Annals Of Hematology 2018, 97: 2245-2248. PMID: 30088044, DOI: 10.1007/s00277-018-3459-6.
- Kumar D, Xu ML. Microenvironment Cell Contribution to Lymphoma Immunity. Frontiers In Oncology 2018, 8: 288. PMID: 30101129, PMCID: PMC6073855, DOI: 10.3389/fonc.2018.00288.
- Romberg N, Le Coz C, Glauzy S, Schickel JN, Trofa M, Nolan BE, Paessler M, Xu M, Lambert MP, Lakhani SA, Khokha MK, Jyonouchi S, Heimall J, Takach P, Maglione PJ, Catanzaro J, Hsu FI, Sullivan KE, Cunningham-Rundles C, Meffre E. Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses. Journal Of Allergy And Clinical Immunology 2018, 143: 258-265. PMID: 29935219, PMCID: PMC6400323, DOI: 10.1016/j.jaci.2018.06.012.
- Rahmani M, Halene S, Xu ML. Small Cell Variant of Intravascular Large B‐Cell Lymphoma: Highlighting a Potentially Fatal and Easily Missed Diagnosis. BioMed Research International 2018, 2018: 9413015. PMID: 29850589, PMCID: PMC5903319, DOI: 10.1155/2018/9413015.
- Kini Bailur J, Mehta S, Zhang L, Neparidze N, Parker T, Bar N, Anderson T, Xu ML, Dhodapkar KM, Dhodapkar MV. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Advances 2017, 1: 2343-2347. PMID: 29296884, PMCID: PMC5729633, DOI: 10.1182/bloodadvances.2017012732.
- Xu ML, O’Malley D. Lymph node stromal and vascular proliferations. Seminars In Diagnostic Pathology 2017, 35: 67-75. PMID: 29173940, DOI: 10.1053/j.semdp.2017.11.004.
- Astle JM, Xu ML, Friedman T, Brown E. Limitations of poor bone marrow aspirations (for an accurate diagnosis) despite the multimodal analytical era: A longitudinal retrospective study. American Journal Of Hematology 2017, 92: e600-e602. PMID: 28670759, DOI: 10.1002/ajh.24839.
- Sharma P, Balasingham S, Stawiarski K, Rahmani M, Costantino A, Sharma P, Xu M, Masoud A. Burkitt lymphoma as a lead point for jejunojejunal intussusception in a human immunodeficiency virus patient. Clinical Journal Of Gastroenterology 2017, 10: 342-350. PMID: 28523628, DOI: 10.1007/s12328-017-0747-y.
- Onuoha C, Arshad J, Astle J, Xu M, Halene S. Novel Developments in Leukopenia and Pancytopenia. Primary Care Clinics In Office Practice 2016, 43: 559-573. PMID: 27866577, DOI: 10.1016/j.pop.2016.07.005.
- Zeidan AM, Xu M, Steensma DP. The importance of erythroblast enumeration in myeloid neoplasia. Annals Of Hematology 2016, 96: 329-330. PMID: 27771743, DOI: 10.1007/s00277-016-2862-0.
- Kim TK, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, Stahl M, Gore SD, Zeidan AM. Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. Annals Of Hematology 2016, 95: 1895-1898. PMID: 27468851, PMCID: PMC10955604, DOI: 10.1007/s00277-016-2761-4.
- Simmons NR, Xu ML, Tavassoli FA, Geisel J, Killelea B, Philpotts LE. A Rare Presentation of Rosai‐Dorfman Disease as a Breast Mass. The Breast Journal 2016, 22: 581-583. PMID: 27345754, DOI: 10.1111/tbj.12635.
- Gauthier AC, Nguyen A, Munday WR, Xu ML, Materin MA. Anterior Chamber Non-Hodgkin Lymphoma of the Iris Masquerading as Uveitis-Glaucoma-Hyphema Syndrome. Ocular Oncology And Pathology 2016, 2: 230-233. PMID: 27843901, PMCID: PMC5091236, DOI: 10.1159/000445119.
- Stahl M, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Annals Of Hematology 2016, 95: 1197-1200. PMID: 27068405, PMCID: PMC7479634, DOI: 10.1007/s00277-016-2664-4.
- Xu M, Li L, Pittenger C. Ablation of fast-spiking interneurons in the dorsal striatum, recapitulating abnormalities seen post-mortem in Tourette syndrome, produces anxiety and elevated grooming. Neuroscience 2016, 324: 321-329. PMID: 26968763, PMCID: PMC4838496, DOI: 10.1016/j.neuroscience.2016.02.074.
- Xu ML, Fedoriw Y. Lymphoma Microenvironment and Immunotherapy. Surgical Pathology Clinics 2016, 9: 93-100. PMID: 26940270, DOI: 10.1016/j.path.2015.10.001.
- Verma R, Mai Z, Xu M, Zhang L, Dhodapkar K, Dhodapkar M. Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs. Blood 2015, 126: 913. DOI: 10.1182/blood.v126.23.913.913.
- Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary. Oncotarget 2015, 6: 13933-13945. PMID: 26101854, PMCID: PMC4546442, DOI: 10.18632/oncotarget.4324.
- Ho C, Yao X, Tian L, Li FY, Podoltsev N, Xu ML. The authors' reply. American Journal Of Clinical Pathology 2015, 143: 309. PMID: 25738202.
- Munday WR, Kapur LH, Xu M, Zhang X. Russell body duodenitis with immunoglobulin kappa light chain restriction. World Journal Of Gastrointestinal Endoscopy 2015, 7: 73-76. PMID: 25610537, PMCID: PMC4295184, DOI: 10.4253/wjge.v7.i1.73.
- Gibson JF, Kapur L, Sokhn J, Xu M, Foss FM. A fatal case of primary cutaneous gamma–delta T‐cell lymphoma complicated by HLH and cardiac amyloidosis. Clinical Case Reports 2014, 3: 34-38. PMID: 25678971, PMCID: PMC4317209, DOI: 10.1002/ccr3.142.
- Xu ML, Cooper D. Caught in transformation. Blood 2014, 124: 2749. PMID: 25513660, DOI: 10.1182/blood-2014-08-593913.
- Ahmad AK, Hui P, Litkouhi B, Azodi M, Rutherford T, McCarthy S, Xu ML, Schwartz PE, Ratner E. Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital Tract. International Journal Of Gynecological Cancer 2014, 24: 1250-1255. PMID: 25010039, PMCID: PMC8139417, DOI: 10.1097/igc.0000000000000201.
- Ho C, Yao X, Tian L, Li FY, Podoltsev N, Xu ML. Marrow Assessment for Hemophagocytic Lymphohistiocytosis Demonstrates Poor Correlation With Disease Probability. American Journal Of Clinical Pathology 2014, 141: 62-71. PMID: 24343738, DOI: 10.1309/ajcpmd5tjefoovbw.
- Fraser J, Subtil A, Alpdogan O, Seropian S, Cooper D, Xu M, Foss F. Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience. Blood 2013, 122: 5092. DOI: 10.1182/blood.v122.21.5092.5092.
- Varughese N, Duong A, Emre S, Xu M, Lee AI. Venting the Spleen. New England Journal Of Medicine 2013, 369: 1357-1363. PMID: 24088096, DOI: 10.1056/nejmcps1210943.
- Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. Clinical Cancer Research 2013, 19: 3462-3473. PMID: 23674495, PMCID: PMC4102335, DOI: 10.1158/1078-0432.ccr-13-0855.
- Alomari A, Hui P, Xu M. Composite Peripheral T-cell Lymphoma Not Otherwise Specified, and B-cell Small Lymphocytic Lymphoma Presenting With Hemophagocytic Lymphohistiocytosis. International Journal Of Surgical Pathology 2012, 21: 303-308. PMID: 23129836, DOI: 10.1177/1066896912464047.
- Xu M, Schwartz P, Rutherford T, Azodi M, Santin A, Silasi D, Martel M, Hui P. HER‐2/neu receptor gene status in endometrial carcinomas: a tissue microarray study. Histopathology 2009, 56: 269-273. PMID: 20102407, DOI: 10.1111/j.1365-2559.2009.03464.x.
- McClaskey J, Xu M, Snyder EL, Tormey CA. Clinical trials for pathogen reduction in transfusion medicine: A review. Transfusion And Apheresis Science 2009, 41: 217-225. PMID: 19793679, DOI: 10.1016/j.transci.2009.09.008.
- Chiang MY, Xu ML, Histen G, Shestova O, Roy M, Nam Y, Blacklow SC, Sacks DB, Pear WS, Aster JC. Identification of a conserved negative regulatory sequence that influences the leukemogenic activity of NOTCH1. Molecular And Cellular Biology 2006, 26: 6261-71. PMID: 16880534, PMCID: PMC1592797, DOI: 10.1128/MCB.02478-05.
- Malecki MJ, Sanchez-Irizarry C, Mitchell JL, Histen G, Xu ML, Aster JC, Blacklow SC. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Molecular And Cellular Biology 2006, 26: 4642-51. PMID: 16738328, PMCID: PMC1489116, DOI: 10.1128/MCB.01655-05.
- Mega MS, Thompson PM, Cummings JL, Back CL, Xu ML, Zohoori S, Goldkorn A, Moussai J, Fairbanks L, Small GW, Toga AW. Sulcal variability in the Alzheimer's brain: correlations with cognition. Neurology 1998, 50: 145-51. PMID: 9443471.